Five Prime Therapeutics, Inc., a San Francisco, CA-based developer of innovative protein and antibody therapeutics, has received a $1m funding from Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society.
The funding will enable the company to develop its pre-clinical stage therapeutic candidate for treatment of Multiple Sclerosis (MS).
Under the terms of the deal, Fast Forward will provide funds to enable pre-clinical testing of a proprietary and innovative biological molecule discovered at FivePrime, which targets specific cells of the innate immune system.
The innate immune system is a component of the body’s immune system and recent research has suggested that it contributes to disease activity in both relapsing remitting and progressive forms of MS.
FinSMEs
25/05/2010